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Summary
Background The interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver 
metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus 
chemotherapy compared with those given chemotherapy alone. The focus of the present analysis was to assess the 
effect on overall survival.
Methods New EPOC was a multicentre, open-label, randomised, controlled, phase 3 trial. Adult patients (aged 
≥18 years) with KRAS wild-type (codons 12, 13, and 61) resectable or suboptimally resectable colorectal liver 
metastases and a WHO performance status of 0–2 were randomly assigned (1:1) to receive chemotherapy with or 
without cetuximab before and after liver resection. Randomisation was done centrally with minimisation factors 
of surgical centre, poor prognosis cancer, and previous adjuvant treatment with oxaliplatin. Chemotherapy 
consisted of oxaliplatin 85 mg/m² administered intravenously over 2 h, l-folinic acid (175 mg flat dose administered 
intravenously over 2 h) or d,l-folinic acid (350 mg flat dose administered intravenously over 2 h), and fluorouracil 
bolus 400 mg/m² administered intravenously over 5 min, followed by a 46 h infusion of fluorouracil 2400 mg/m² 
repeated every 2 weeks (regimen one), or oxaliplatin 130 mg/m² administered intravenously over 2 h and oral 
capecitabine 1000 mg/m² twice daily on days 1–14 repeated every 3 weeks (regimen two). Patients who had received 
adjuvant oxaliplatin could receive irinotecan 180 mg/m² intravenously over 30 min with fluorouracil instead of 
oxaliplatin (regimen three). Cetuximab was given intravenously, 500 mg/m² every 2 weeks with regimen one and 
three or a loading dose of 400 mg/m² followed by a weekly infusion of 250 mg/m² with regimen two. The primary 
endpoint of progression-free survival was published previously. Secondary endpoints were overall survival, 
preoperative response, pathological resection status, and safety. Trial recruitment was halted prematurely on the 
advice of the Trial Steering Committee on Nov 1, 2012. All analyses (except safety) were done on the intention-to-
treat population. Safety analyses included all randomly assigned patients. This trial is registered with ISRCTN, 
number 22944367.
Findings Between Feb 26, 2007, and Oct 12, 2012, 257 eligible patients were randomly assigned to chemotherapy 
with cetuximab (n=129) or without cetuximab (n=128). This analysis was carried out 5 years after the last patient 
was recruited, as defined in the protocol, at a median follow-up of 66·7 months (IQR 58·0–77·5). Median 
progression-free survival was 22·2 months (95% CI 18·3–26·8) in the chemotherapy alone group and 15·5 months 
(13·8–19·0) in the chemotherapy plus cetuximab group (hazard ratio [HR] 1·17, 95% CI 0·87–1·56; p=0·304). 
Median overall survival was 81·0 months (59·6 to not reached) in the chemotherapy alone group and 55·4 months 
(43·5–71·5) in the chemotherapy plus cetuximab group (HR 1·45, 1·02–2·05; p=0·036). There was no significant 
difference in the secondary outcomes of preoperative response or pathological resection status between groups. 
Five deaths might have been treatment-related (one in the chemotherapy alone group and four in the chemotherapy 
plus cetuximab group). The most common grade 3–4 adverse events reported were: neutrophil count decreased 
(26 [19%] of 134 in the chemotherapy alone group vs 21 [15%] of 137 in the chemotherapy plus cetuximab group), 
diarrhoea (13 [10%] vs 14 [10%]), skin rash (one [1%] vs 22 [16%]), thromboembolic events (ten [7%] vs 11 [8%]), 
lethargy (ten [7%] vs nine [7%]), oral mucositis (three [2%] vs 14 [10%]), vomiting (seven [5%] vs seven [5%]), 
peripheral neuropathy (eight [6%] vs five [4%]), and pain (six [4%] vs six [4%]).
Interpretation Although the addition of cetuximab to chemotherapy improves the overall survival in some studies in 
patients with advanced, inoperable metastatic disease, its use in the perioperative setting in patients with operable 
disease confers a significant disadvantage in terms of overall survival. Cetuximab should not be used in this setting.
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Introduction
Colorectal cancer is the fourth most common cancer in 
the UK. Substantial improvements in its management, 
with increasingly sophisticated combinations of systemic 
therapy and surgery, together with earlier diagnosis, 
have resulted in more than a doubling of the 5-year 
survival from 25% to 50% in the past 50 years. In the 
setting of metastatic disease, outcomes are improving 
and, after liver resection, approximately 30% of patients 
will be long-term survivors.1 Unfortunately, the majority 
of patients will have disease recurrence.
The EPOC study (EORTC 40983) showed an 
improvement in progression-free survival of 7% with the 
addition of perioperative systemic chemotherapy to 
surgical resection for colorectal liver metastasis.2 As a 
consequence, this treatment has become standard of care 
in most UK centres.3 The New EPOC study was a logical 
progression from the EPOC study, assessing the benefit 
of adding cetuximab, an antibody to EGFR with confirmed 
efficacy in advanced disease,4 to peri operative systemic 
chemo therapy. Unexpectedly, this addition resulted in a 
shorter progression-free survival in the patients treated 
with cetuximab, and the study was closed to recruitment 
by the trial steering committee on advice from the 
independent data monitoring committee on Nov 1, 2012. 
The previously published results of the interim analysis 
showed the progression-free survival in the chemotherapy 
alone group to be 20·5 months (16·8–26·7), compared 
with 14·1 months (95% CI 11·8–15·9) in the chemotherapy 
plus cetuximab group, with a hazard ratio (HR) of 1·48 
(1·04–2·12; p=0·030),5 at a median follow-up of 21 months.
Since the New EPOC trial began accrual (Feb 26, 2007), 
several studies have evaluated the use of antibodies to 
EGFR in advanced colorectal cancer. Some studies found 
improved outcomes,6,7 whereas others showed no 
difference.8,9 Importantly, none have shown a detriment 
similar to the previously published New EPOC study. 
The present analysis was done after long-term follow-up 
of patients using a more complete dataset, not available 
at the time of the interim analysis, to assess the effect of 
the combination treatment on overall survival.
Methods
Study design and participants
This multicentre, open-label, randomised, controlled, 
phase 3 study was coordinated by the Cancer Research 
UK Southampton Clinical Trials Unit. All patients were 
recruited from 39 UK National Health Service hospitals 
(appendix pp 3, 4), in secondary care settings.
Eligible patients were aged 18 years or older, with a 
WHO performance status of 2 or lower, and resectable 
or suboptimally resectable colorectal liver metastasis 
without detectable extrahepatic distant metastatic 
disease. There was no limit to the number of metastases. 
The protocol mandated that the primary cancer should 
be resected before trial entry or deemed resectable. 
Patients were excluded if they had any uncontrolled 
medical comorbidity likely to interfere with treatment or 
Research in context
Evidence before this study
Before designing the New EPOC trial, PubMed, American 
Society of Clinical Oncology abstracts, and European Society of 
Medical Oncology abstracts were searched for articles published 
in English using the search terms “colorectal cancer”, “colorectal 
liver metastases”, “chemotherapy”, “epidermal growth factor 
receptor”, “cetuximab”, and “panitumumab”. The search was 
done in January, 2006, and no date restrictions were applied. 
No meta-analysis was carried out, as in 2006 only 
one adequately powered trial of perioperative chemotherapy 
had been done.
Survival outcomes of chemotherapy for advanced colorectal 
cancer have improved during the past two decades, in part 
because of improvements in systemic therapies, including 
targeted therapies such as cetuximab, an antibody to EGFR. 
Some, but not all, studies of chemotherapy plus cetuximab 
have shown the combination to improve the overall survival of 
patients with advanced inoperable KRAS wild-type colorectal 
cancer. By contrast, the interim analysis of the New EPOC 
randomised trial showed that this combination significantly 
shortened progression-free survival in patients with operable 
colorectal liver metastases. At that time, overall survival data 
were immature.
Added value of this study
This mature analysis shows that in the perioperative setting, 
cetuximab shortens overall survival by 2 years compared with 
chemotherapy alone. This detriment was most notable in 
patients who had features suggestive of a better prognosis and, 
crucially, post-progression survival was significantly worse. 
Toxicity from systemic therapy and complications of surgery 
could not explain these findings.
Implications of all the available evidence
This study suggests that the addition of cetuximab to 
chemotherapy in the perioperative setting in patients with
operable colorectal liver metastases induces, in some
individuals, multisite metastatic recurrence and a shorter 
overall survival than does chemotherapy alone. These data 
emphasise that the use of biological agents might have 
unpredictable results compared with conventional 
chemotherapy. Cetuximab should not be used in patients with 
operable colorectal liver metastases.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
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assessment of response; any psychiatric or neurological 
disorder affecting ability to consent or comply with 
medication; partial or complete bowel obstruction; pre-
existing peripheral neuropathy of grade 1 or worse 
according to common toxicity criteria; a personal or 
family history of dihydropyrimidine dehydrogenase 
deficiency, Gilbert’s syndrome, or other congenital 
abnormality of biliary transport; platelet counts less than 
100 × 10⁹ per L, an absolute neutrophil count less than 
1·5 × 10⁹ cells per L, serum bilirubin greater than one and 
a quarter times the upper limit of normal, or alkaline 
phosphatase greater than five times the upper limit of 
normal; serum aminotransferase (either aspartate 
aminotransferase or alanine aminotransferase) greater 
than two and a half times the upper limit of normal; or 
estimated creatinine clearance (by Cockcroft formula) of 
less than 50 mL/min or measured glomerular filtration 
rate of less than 50 mL/min. Patients with another 
previous or current malignant disease, which, in the 
judgment of the treating investigator, was likely to 
interfere with the study treatment or assessment of 
response were also excluded.
After the start of the trial, data emerged to support a 
benefit of cetuximab only in KRAS wild-type cancers, 
which led to a protocol amendment (July 8, 2008) to 
exclude patients with mutated KRAS. All patients accrued 
thereafter had confirmed KRAS wild-type status of the 
primary colorectal cancer (codons 12, 13, and 61). After 
completion of the study, a subset of tissue specimens 
were analysed for expanded RAS/RAF mutation status 
(see appendix p 5).
The study was approved by the South West Research 
Ethics Committee. Written, informed consent was 
obtained from all patients before random assignment.
Randomisation and masking
Eligible patients were randomly assigned (1:1) to 
chemotherapy alone or chemotherapy plus cetuximab. 
Treatment assignments were made over the telephone 
by the Medical Research Council Clinical Trials Unit 
with the use of randomised minimisation factors with 
20% random element. The first 52 patients were 
randomly assigned on the basis of nine stratification 
factors. A protocol amendment was then implemented 
on April 22, 2009, to condense the stratification factors to 
surgical centre, poor prognostic cancer (yes vs no), and 
previous treatment with oxaliplatin as adjuvant (yes vs 
no). Poor prognostic cancer was defined as one or more 
of: four or more metastases; N2 disease (according to the 
tumour, node, and metastasis [TNM] staging system); or 
poor differentiation of primary cancer. The amendment 
was made because the trial management group thought 
that the initial large number of stratification factors 
would be less effective at achieving balance between 
the treatment groups, as well as being logistically 
complicated. There was no masking of either investi-
gators or patients to treatment allocation.
Procedures
Patients were randomly assigned to chemotherapy with 
or without cetuximab for 12 weeks, followed by surgery 
and then a further 12 weeks of chemotherapy with or 
without cetuximab. Chemotherapy consisted of 
oxaliplatin 85 mg/m² administered intravenously over 
2 h, l-folinic acid (175 mg flat dose administered 
intravenously over 2 h) or d,l-folinic acid (350 mg flat 
dose administered intravenously over 2 h), and 
5-fluorouracil bolus 400 mg/m² administered intra-
venously over 5 min, followed by a 46-h infusion of 
fluorouracil 2400 mg/m² repeated every 2 weeks 
(regimen one), or oxaliplatin 130 mg/m² administered 
intravenously over 2 h and oral capecitabine 1000 mg/m² 
twice daily on days 1–14 repeated every 3 weeks 
(regimen two). Patients who had received adjuvant 
oxaliplatin could receive irinotecan 180 mg/m² intra-
venously over 30 min with fluorouracil instead of 
oxaliplatin (regimen three). Choice of regimen was 
determined according to previous oxaliplatin exposure 
and clinician and patient choice. Cetuximab was given as 
an intravenous dose of 500 mg/m² every 2 weeks with 
regimens one and three or a loading dose of 400 mg/m² 
followed by a weekly infusion of 250 mg/m² with 
regimen two. Detailed dose reduction schedules are in 
the protocol (appendix pp 34–127). Briefly, 20% dose 
reductions of chemotherapy were made for 
haematological or gastrointestinal toxic effects and dose 
delays of 2 weeks or longer were made for cetuximab 
toxic effects.
There were several protocol changes throughout the 
duration of the study (appendix pp 17, 18). The most 
important ones related to the restriction of recruitment 
to patients with KRAS wild-type cancers and the change 
in the sample size based on the predicted effect size from 
other studies.
All surgery was done in high-volume liver centres in 
the UK with expertise in complex liver resections. The 
protocol stipulated that all sites of metastatic disease 
(including those responding to neoadjuvant therapy) 
were resected. In the original trial protocol, written in 
2006, it was suggested that a resection margin of 
10 mm should be achieved when possible. In the past 
decade, the consensus on the need for such a large 
margin has changed, but the protocol was not amended. 
Staged resection was allowed, as was synchronous 
resection of the primary cancer. Treatment with ablation 
was not permitted by the protocol.
All patients were followed up every 3 months for the 
first 2 years and every 6 months for a further 3 years until 
progression or death. At these visits, patients under-
went a clinical examination, chest–abdomen–pelvis CT, 
and laboratory investigations, and completed quality-
of-life assessments. CT or MRI scans were done to 
assess Response Evaluation Criteria In Solid Tumors 
(RECIST; version 1.0) before systemic treatment. The 
multi disciplinary team managing the patient established 
Articles
www.thelancet.com/oncology   Vol 21   March 2020 401
disease progression; external radiological review was not 
done. Adverse events and safety were assessed using 
the Common Terminology Criteria for Adverse Events 
version 3 before each cycle unless there was a presen-
tation earlier.
Criteria for treatment to be discontinued were: 
progression while on therapy, unacceptable toxicity, 
inter current illness preventing further treatment, 
withdrawal of consent for treatment by the patient, or 
any alterations in the patient’s condition that justified the 
discontinuation of treatment in the investigator’s 
opinion.
After Nov 1, 2012, when the predefined futility criteria 
were met (using a method proposed by Freidlin and 
colleagues10 when the lower limit of the 95% CI for the 
progression-free survival HR was >1), the trial steering 
committee, on advice from the independent data 
monitoring committee, requested that cetuximab admin-
istration was stopped. Treatment defaulted to standard of 
care, which, for most patients, was contin uation of 
chemotherapy alone. Data collection to inform outcomes 
was continued.
Outcomes
The primary outcome was progression-free survival, 
which was defined as the time from randomisation to 
disease progression or death from any cause, whichever 
occurred first, and has been previously reported.5 Patients 
without disease progression or death were censored at 
the date of the last assessment. The objective of this 
present study was to assess the secondary endpoint of 
overall survival, defined as the time from randomisation 
to death from any cause. Patients still alive were censored 
at the time of last follow-up. Long-term death data were 
obtained via patient registration with National Health 
Service (NHS) Digital. As such, the assumption was 
made that any patient not recorded as having died could 
be assumed alive (and censored) 2 months before the 
NHS Digital date of assessment of patient status (ie, this 
excluded the possibility of missing a death event as the 
death had not yet reached the NHS Digital database). For 
the evaluation of progression-free survival, patients lost 
to follow-up without progression were censored at the 
date of the last assessment, irrespective of whether or not 
the date of death was received subsequently via NHS 
Digital. Other secondary outcomes were preoperative 
response (response after the end of the preoperative 
treatment period, assessed using RECIST), pathological 
resection status (margin ≥1 cm, <1 cm, or cancer on cut 
surface), safety, quality of life, and cost-effectiveness. 
Quality-of-life and cost-effectiveness analyses were not 
done because the trial was negative. Other prespecified 
exploratory outcomes were post-progression survival in 
the primary analysis population who progressed and 
progression-free survival and overall survival in: patients 
treated with oxaliplatin, fluorouracil, and folinic acid; 
patients who responded to preoperative chemotherapy; 
patients with left-sided cancers; and patients with right-
sided cancers. All analyses presented were prespecified 
in the statistical analysis plan that was updated for this 
mature analysis (appendix pp 196–291).
Statistical analysis
The accrual target of the study was revised on Jan 16, 2012, 
at the suggestion of the trial steering committee after a 
reconsideration of the potential effect of KRAS wild-type 
restriction. The revised sample size needed 268 patients 
(and 212 disease progression events) in patients with 
wild-type KRAS (codons 12, 13, and 61), under the 
assumptions of a log-rank test HR of 0·68, 80% power, 
5% two-sided significance level, 5% loss to follow-up, 
3-year recruitment, 5 years of follow-up, and progression-
free survival in the chemotherapy alone group of 67% at 
1 year, 46% at 2 years, and 35% at 3 years. There was no 
correction of the p value to adjust for the previous 
analysis.
An a-priori statistical analysis plan was devised for all 
analyses of these long-term data. Survival was described 
using Kaplan-Meier curves and compared using Cox 
proportional hazards models. The efficacy analyses were 
done on the primary analysis population (composed of 
the intention-to-treat population including all patients 
with known KRAS [codons 12, 13, and 61] wild-type status 
who had data available for the analysis being done), with 
HRs (95% CIs) and 2-sided p values being calculated. 
Safety analyses included all randomly assigned patients 
and involved calculating frequencies and percentages. 
There was no adjustment for multiple comparisons. The 
primary analysis used an unadjusted Cox proportional 
hazards model, but a sensitivity analysis was also done, 
adjusting the model for the minimisation factors. For all 
Cox proportional hazards models fitted, the assumption 
of proportional hazards was checked by visually 
inspecting the complementary log-log (event times) 
versus log (time) plot.
Prespecified exploratory interaction subgroup analyses 
assessed whether the effect of cetuximab on progression-
free survival and overall survival was different depending 
on backbone treatment, concentration of carcino-
embryonic antigen at diagnosis, lymph node-positive 
primary cancer, poor differentiation at biopsy, number 
and size of liver metastases, extrahepatic involve ment, 
previous treatment with oxaliplatin, synchronous versus 
non-synchronous presentation of disease, performance 
status, resection status of primary cancer at study entry, 
updated RAS/RAF mutation status, number of weeks of 
postoperative chemotherapy received by the patient, and 
preoperative response.
To test for consistencies in the size of any effect of 
chemotherapy and cetuximab, a χ² test for interaction 
was done.
STATA (version 15.1) and SAS (version 9.4) were used 
for all analyses. Data were reviewed by the Data 
Monitoring and Ethics Committee.
For NHS Digital see 
https://digital.nhs.uk/
Articles
402 www.thelancet.com/oncology   Vol 21   March 2020
This study is registered with the International 
Standard Randomised Controlled Trial registry (number 
22944367), with ClinicalTrials.gov (number 00482222), and 
with the UK Clinical Research Network (number 2068).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. TM, AW, and LS had full access to all the data 
in the study and all authors had final responsibility for 
the decision to submit for publication.
Results
272 patients were recruited from 39 institutions in the 
UK between Feb 26, 2007, and Oct 12, 2012, and randomly 
assigned to treatment. One patient was incorrectly 
assigned by mistake (ie, the patient was eligible but the 
centre was asked to proceed with the opposite treatment 
to the one they had been assigned to), and was excluded 
from all analyses. An additional 14 patients (six in the 
chemotherapy alone group and eight in the chemotherapy 
plus cetuximab group), who were randomly assigned 
before the amendment necessitating KRAS status testing 
and were retrospectively shown to have a KRAS mutation 
or indeterminate KRAS status, were also excluded from 
all analyses, except safety analyses. As such, the primary 
analysis population consisted of 257 patients, of whom 
128 patients were randomly assigned to received 
chemotherapy alone and 129 to receive chemotherapy 
plus cetuximab (figure 1). One patient assigned to the 
chemotherapy plus cetuximab group was lost to follow-
up. Table 1 shows the baseline characteristics, similar to 
those published previously.5
87 (68%) of 128 patients in the chemotherapy alone 
group versus 89 (69%) of 129 patients in the chemotherapy 
plus cetuximab group received oxaliplatin, 5-fluorouracil, 
and folinic acid backbone treatment (regimen 1). Smaller 
proportions of patients received capecitabine and 
oxaliplatin (regimen 2; 27 [21%] of 128 vs 24 [19%] of 129) 
or irinotecan, 5-fluorouracil, and folinic acid (regimen 3; 
11 [9%] of 128 vs 15 [12%] of 129). The patients who had 
previous oxaliplatin adjuvant therapy or another contra-
indication to oxaliplatin were treated using regimen 3. 
Data on relative dose intensity are in the appendix 
(pp 19–24).
In this updated analysis, the median follow-up time 
was 66·7 months (IQR 58·0–77·5): 66·9 months 
(58·3–77·5) for patients in the chemo therapy alone 
group and 65·0 months (57·0–77·5) in the chemotherapy 
plus cetuximab group. For the progression-free survival 
updated analysis there were 180 events (89 in the 
chemotherapy alone group and 91 in the chemotherapy 
plus cetuximab group; since the preliminary analysis in 
2013, 57 additional events had occurred [33 in the 
chemotherapy alone group and 24 in the chemo therapy 
plus cetuximab group]). The unadjusted HR for 
progression-free survival was 1·17 (95% CI 0·87–1·56; 
p=0·304) for chemotherapy without versus with 
cetuximab, with an observed median progression-
free survival of 22·2 months (95% CI 18·3–26·8) in the 
chemo therapy alone group and 15·5 months (13·8–19·0) 
in the chemotherapy plus cetuximab group (figure 2A). 
551 excluded
        402 did not meet inclusion criteria
        104 by patient’s or clinician’s choice
           45 other reasons
272 patients randomly assigned
1 incorrectly assigned 
137 allocated to the chemotherapy plus cetuximab 
        group and included in safety analyses 
134 allocated to the chemotherapy alone group and 
         included in safety analyses
6 not KRAS wild-type (codons 12/31/61)
128 included in the primary analysis population 
 113 operated
  59 completed postoperative chemotherapy
129 included in the primary analysis population 
 108 operated
   62 completed postoperative chemotherapy
823 patients assessed for eligibility
8 not KRAS wild-type (codons 12/31/61)
Figure 1: Trial profile
Chemotherapy 
alone group 
(n=128)
Chemotherapy 
plus cetuximab 
group (n=129)
Age (years)* 65 (59–70) 64 (59–69)
Sex
Female 47 (37%) 37 (29%)
Male 81 (63%) 92 (71%)
WHO performance status 0 or 1 128 (100%) 126 (98%)
Primary cancer
T3 or T4† 107 (84%) 109 (84%)
N1 or N2† 83 (65%) 78 (60%)
Poorly differentiated 10 (8%) 15 (12%)
Unresected‡ 9 (7%) 18 (14%)
1–3 liver metastases 103 (80%) 97 (75%)
One metastasis >3 cm 63 (49%) 75 (58%)
Synchronous metastases‡ 73 (57%) 88 (68%)
Carcinoembryonic antigen 
>30 ng/mL
31 (24%) 34 (26%)
Extrahepatic disease 3 (2%) 6 (5%)
Data are median (IQR) or n (%). *In the previous publication, age was reported as 
mean (IQR).5 †According to the tumour, node, metastasis (TNM) staging system. 
‡Data updated since the previous publication, which reported unresected primary 
cancer at trial entry in 13 (10%) patients in the chemotherapy alone group and 
18 (14%) patients in the chemotherapy plus cetuximab group and synchronous 
metastases in 60 (47%) patients in the chemotherapy alone group and 68 (53%) 
patients in the chemotherapy plus cetuximab group.5
Table 1: Baseline characteristics (primary analysis population)
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The sensitivity analysis adjusting for the minimisation 
factors gave a similar result (HR 1·13, 0·84–1·52; 
p=0·401; appendix p 27).
130 patients died and most deaths were disease-related, 
accounting for 54 (93%) of 58 deaths in the chemotherapy 
alone group and 67 (93%) of 72 deaths in the chemo-
therapy plus cetuximab group. The remaining nine (7%) 
deaths were due to other causes (four [7%] in the 
chemotherapy alone group and five [7%] in the 
chemotherapy plus cetuximab group; appendix p 29). 
The addition of cetuximab to chemo therapy resulted in 
an unadjusted HR for overall survival of 1·45 (95% CI 
1·02–2·05; p=0·036), with an observed median overall 
survival of 81·0 months (59·6–not reached) in the 
chemotherapy alone group and 55·4 months (43·5–71·5) 
in the chemotherapy plus cetuximab group (figure 2B). 
The sensitivity analysis adjusting for the minimisation 
factors gave a similar result (HR 1·44, 1·02–2·05; 
p=0·040; appendix p 27).
The response to preoperative chemotherapy is shown in 
the appendix (p 25). Complete or partial response occurred 
in 78 (61%) of 128 patients receiving chemotherapy alone 
and in 93 (72%) of 129 patients receiving chemo therapy 
plus cetuximab. There was no significant difference in the 
proportion of patients achieving a response between 
treatment groups (p=0·383).
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Figure 2: Progression-free survival (A) and overall survival (B) in the primary analysis population
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Surgical information is presented in table 2. 221 (86%) 
of 257 randomly assigned patients underwent an 
operation, among whom 108 (96%) of 113 patients in the 
chemotherapy alone group and 100 (93%) of 108 patients 
in the chemotherapy plus cetuximab group proceeded to 
resection. Most patients who underwent an operation 
had a R0 resection (89 [82%] of 108 in the chemotherapy 
alone group and 79 [79%] of 100 in the chemotherapy 
plus cetuximab group).
The median post-progression survival (among 
167 patients, of whom 82 were in the chemotherapy alone 
group and 85 in the chemotherapy plus cetuximab 
group) was 33·5 months (95% CI 25·3–41·2) in the 
chemotherapy alone group compared with 23·5 months 
(16·0–31·3) in the chemotherapy plus cetuximab group 
(HR 1·55, 1·07–2·24; p=0·020; appendix p 16).
The progression-free survival and overall survival in 
patients in the primary analysis popu lation treated with 
the chemotherapy backbone of oxaliplatin, 5-fluorouracil, 
and folinic acid and in the subpopulations of patients 
who responded to preoperative chemotherapy, who had 
left-sided cancers, and who had right-sided cancers were 
explored in prespecified analyses and are shown in 
Chemotherapy 
alone group 
(n=128)
Chemotherapy 
plus cetuximab 
group (n=129)
Operated* 113/128 (88%) 108/129 (84%)
Resected† 108/113 (96%) 100/108 (93%)
From sole resection/first resection
One monosegmentectomy or 
wedge resection ‡
20/108 (19%) 29/100 (29%)
One plurisegmentectomy (major 
resection, two or more segments)‡
54/108 (50%) 46/100 (46%)
Multiple resections (major and 
minor, minor and minor, etc)‡
34/108 (31%) 25/100 (25%)
Number of patients who had staged 
resections‡
3/108 (3%) 6/100 (6%)
From second resection
One monosegmentectomy or 
wedge resection ‡
1/108 (1%) 2/100 (2%)
One plurisegmentectomy (major 
resection, two or more segments)‡
1/108 (1%) 1/100 (1%)
Multiple resections (major and 
minor, minor and minor, etc)‡
0 3/100 (3%)
NA (ablation performed)‡ 1/108 (1%) 0
Not resected† 5/113 (4%) 8/108 (7%)
Complete response§ 0 2/8 (25%)
Irresectable disease§ 3/5 (60%) 1/8 (13%)
Microwave ablation performed§ 1/5 (20%) 0
RFA performed§ 1/5 (20%) 5/8 (63%)
Not operated* 15/128 (12%) 21/129 (16%)
Inadequate future liver remnant¶ 1/15 (7%) 0
Inoperable at baseline in 
retrospect¶
1/15 (7%) 2/21 (10%)
Patient refused surgery¶ 0 1/21 (5%)
Portal vein thrombosis¶ 0 1/21 (5%)
Progressive disease¶ 3/15 (20%) 11/21 (52%)
Radiological complete response¶ 2/15 (13%) 0
Unfit for surgery¶ 4/15 (27%) 2/21 (10%)
Withdrew or died before surgery¶ 4/15 (27%) 4/21 (19%)
Any ablation† 5/113 (4%) 11/108 (10%)
Cancer on specimen‡
From sole resection or first resection
Macroscopic‡ 87/108 (81%) 81/100 (81%)
Only microscopic residual‡3 11/108 (10%) 9/100 (9%)
No residual cancer‡ 10/108 (9%) 7/100 (7%)
Other‡ 0/108 (0%) 2/100 (2%)
Missing (limited surgery 
information available)‡
0/108 (0%) 1/100 (1%)
From second resection
Macroscopic‡ 1/108 (1%) 5/100 (5%)
Only microscopic residual‡ 0/108 (0%) 1/100 (1%)
No residual cancer‡ 1/108 (1%) 0
(Table 2 continues in next column)
Chemotherapy 
alone group 
(n=128)
Chemotherapy 
plus cetuximab 
group (n=129)
(Continued from previous column)
NA (ablation performed)‡ 1/108 (1%) 0
Shortest macroscopic margin between cancer and cut surface
From sole resection or first resection
Margin ≥1cm‡ 36/108 (33%) 29/100 (29%)
Margin <1cm‡ 54/108 (50%) 49/100 (49%)
No margin (cancer visible on cut 
surface)‡
8/108 (7%) 12/100 (12%)
NA (no residual cancer)‡ 10/108 (9%) 7/100 (7%)
Missing (limited surgery 
information available or ablation)‡
0/108 (0%) 3/100 (3%)
From second resection
Margin ≥1cm‡ 1/108 (1%) 2/100 (2%)
Margin <1cm‡ 0 3/100 (3%)
No margin (cancer visible on cut 
surface)‡
0 0
Not applicable (no residual 
cancer)‡
1/108 (1%) 0
NA (ablation performed)‡ 1/108 (1%) 1/100 (1%)
At least one surgical complication 28/113 (25%) 27/108 (25%)
Death during surgery† 0 0
Postoperative death (30 days after 
liver resection)†
0 1/108 (1%)
Data are n/N (%). The numbers in this table represent all surgeries carried out. 
Patients who had their resection staged are counted twice as this information 
was recorded for each surgery. RFA=radiofrequency ablation. NA=not applicable. 
*Denominator is the number of patients in the primary analysis population. 
†Denominator is the number of patients in the primary analysis population who 
have had an operation (before disease progression). ‡Denominator is the number 
of patients in the primary analysis population who have had an operation (before 
disease progression) and had a resection. §Denominator is the number of patients 
in the primary analysis population who have had an operation (before disease 
progression), but not a resection. ¶Denominator is the number of patients in the 
primary analysis population who did not have an operation (before disease 
progression).
Table 2: Surgical information and postoperative complications (primary 
analysis population)
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10·1 10
Favours chemotherapy aloneFavours chemotherapy plus cetuximab 
(Events/patients)
Hazard rario
(95% CI)
pinteraction 
value
Chemotherapy 
alone group
CEA concentration at time of diagnosis
  >30 ng/mL
  ≤30 ng/mL
Lymph node-positive primary cancer
  Yes
  No
Poor differentiation at biopsy
  Yes
  No
Number of liver metastases
  ≥4
  1–3
Cancer diameter >3 cm 
  Yes
  No
Extrahepatic involvement
  Yes
  No
≥4 metastases, poorly differentiated cancers, or N2
  Yes
  No
Previous treatment with oxaliplatin
  Yes
  No
Presentation of disease
  Synchronous
  Non-synchronous
Performance status
  0
  1 or 2
Resection status of primary cancer at trial entry
  Resected
  Unresected
Site of primary cancer
  Left
  Right
Backbone treatment
  OxMdG 
  IrMdG
  CAPOX
Updated RAS/RAF status
  RAS/RAF mutated*
  RAS/RAF non mutated†
  KRAS non mutated‡
Number of weeks of postoperative chemotherapy 
  0 
  1–11 
  12 
Preoperative response
  Complete or partial response
  Stable or progressive disease
Overall
Chemotherapy
plus cetuximab group
 19/31
 39/93
 43/83
 13/42
 
 6/10
 45/109
 14/25
 44/103
 35/62
 23/66
 2/3
 56/125
 36/68
 22/60
 5/11
 53/117
 37/73
 21/55
 35/86
 23/42
 54/119
 4/9
 46/103
 12/25
 35/87
 5/11
 17/27
 7/12
 18/49
 33/67
 33/54
 5/15
 20/59
 32/78
 21/42
 58/128
 20/33
 50/92
 44/77
 22/41
 6/15
 63/108
 21/32
 51/96
 43/73
 29/55
 5/6
 67/122
 37/71
 34/56
 6/15
 66/113
 50/87
 22/41
 43/86
 29/42
 60/110
 12/18
 52/99
 20/29
 47/89
 8/15
 17/24
 6/12
 32/67
 34/49
 36/49
 6/17
 30/62
 47/93
 24/33
 
 72/128
0·345
0·129
0·044
0·886
0·359
0·732
0·01
0·237
0·368
0·802
0·396
0·473
0·927
0·437
0·889
0·235
1·03 (0·55–1·94)
1·52 (1·00–2·30)
1·20 (0·79–1·83)
2·22 (1·11–4·41)
0·60 (0·19–1·88)
1·76 (1·20–2·58)
1·38 (0·70–2·73)
1·44 (0·96–2·16)
1·21 (0·78–1·90)
1·68 (0·97–2·90)
1·19 (0·23–6·25)
1·41 (0·99–2·01)
0·95 (0·60–1·51)
2·35 (1·37–4·03)
0·78 (0·24–2·58)
1·57 (1·09–2·25)
1·27 (0·83–1·95)
1·77 (0·97–3·23)
1·43 (0·92–2·24)
1·50 (0·87–2·60)
1·35 (0·93–1·95)
2·23 (0·71–6·94)
1·34 (0·90–1·99)
1·79 (0·87–3·67)
1·52 (0·98–2·36)
1·28 (0·42–3·94)
1·47 (0·74–2·89)
0·85 (0·28–2·55)
1·64 (0·92–2·93)
1·70 (1·05–2·75)
1·60 (0·99–2·57)
1·14 (0·35–3·75)
1·62 (0·92–2·86)
1·41 (0·90–2·21)
2·16 (1·19–3·91)
1·45 (1·02–2·05)
(Events/patients)
Figure 3: Forest plot for 
overall survival
CAPOX=capecitabine and 
oxaliplatin. 
CEA=carcinoembryonic 
antigen. IrMdG=irinotecan, 
5-ﬂuorouracil, and folinic acid. 
OxMdG=oxaliplatin, 
5-ﬂuorouracil, and folinic acid. 
*Mutation identified in 
primary cancer in KRAS 
(codons 12/13/61/117,146), 
NRAS (codons 
12/13/61/117,146), or BRAF 
(V600E). †No mutation 
identified in primary cancer in 
KRAS (codons 
12/13/61/117,146), NRAS 
(codons 12/13/61/117,146), or 
BRAF (V600E). ‡No mutation 
identified in primary cancer in 
KRAS (codons 12/13/61); no 
testing for remaining 
mutations (ie, KRAS [codons 
117,146], NRAS [codons 
12/13/61/117,146], 
or BRAF [V600E]).
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Chemotherapy alone group Chemotherapy plus cetuximab group
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
During preoperative chemotherapy period*
Blood and lymphatic system disorders
Anaemia 64 (48%) 0 0 0 58 (42%) 1 (1%) 0 0
Febrile neutropenia ·· 2 (1%) 0 0 ·· 0 0 0
Other (platelets) 56 (42%) 4 (3%) 0 0 39 (28%) 0 0 0
Other (white cell count low) 36 (27%) 5 (4%) 0 0 38 (28%) 4 (3%) 0 0
Cardiac disorders
Acute coronary syndrome ·· 1 (1%) 0 0 ·· 0 0 0
Cardiac arrest ·· 0 0 0 ·· 0 0 1 (1%)
Cardiac chest pain ·· 1 (1%) 0 0 ·· 0 0 0
Heart failure ·· 0 0 1 (1%) ·· 0 0 0
Pericarditis ·· 0 1 (1%) 0 ·· 0 0 0
Ear and labyrinth disorders
Hearing impaired ·· 1 (1%) 0 0 ·· 0 0 0
Eye disorders
Conjunctivitis ·· 0 0 0 ·· 1 (1%) 0 0
Other (transient visual disturbance) ·· 0 0 0 ·· 1 (1%) 0 0
Gastrointestinal disorders
Abdominal pain ·· 3 (2%) 0 0 ·· 0 0 0
Constipation 35 (26%) 0 0 0 41 (30%) 1 (1%) 0 0
Diarrhoea 78 (58%) 12 (9%) 0 0 81 (59%) 12 (9%) 0 0
Gastroesophageal reﬂux disease or dyspepsia 18 (13%) 0 0 0 27 (20%) 1 (1%) 0 0
Mucositis oral 56 (42%) 3 (2%) 0 0 90 (66%) 11 (8%) 0 0
Nausea 78 (58%) 3 (2%) 0 0 66 (48%) 3 (2%) 0 0
Obstruction gastric ·· 1 (1%) 0 0 ·· 0 0 0
Vomiting 31 (23%) 4 (3%) 0 0 24 (18%) 4 (3%) 1 (1%) 0
General disorders and administration-site conditions
Fever ·· 1 (1%) 0 0 ·· 1 (1%) 0 0
Non-cardiac chest pain ·· 1 (1%) 0 0 ·· 0 0 0
Hepatobiliary disorders
Hepatic haemorrhage ·· 0 0 0 ·· 1 (1%) 0 0
Immune system disorders
Allergic reaction ·· 1 (1%) 0 0 ·· 1 (1%) 0 0
Anaphylaxis ·· 0 0 0 ·· 1 (1%) 0 0
Infections and infestations
Abdominal infection ·· 1 (1%) 0 0 ·· 0 0 0
Device-related infection ·· 1 (1%) 0 0 ·· 4 (3%) 0 0
Infection ·· 2 (1%) 0 0 ·· 1 (1%) 0 0
Lung infection ·· 0 0 0 ·· 2 (1%) 0 0
Other (Escherichia coli infection) ·· 0 0 0 ·· 1 (1%) 0 0
Other (infection of unknown aetiology) ·· 0 0 0 ·· 1 (1%) 0 0
Other (Clostridioides difficile infection) ·· 1 (1%) 0 0 ·· 0 0 0
Sepsis ·· 0 1 (1%) 0 ·· 2 (1%) 1 (1%) 0
Upper respiratory tract infection ·· 1 (1%) 0 0 ·· 0 0 0
Investigations
Deranged liver function tests ·· 0 0 0 ·· 3 (2%) 0 0
Neutrophil count decreased 50 (37%) 14 (10%) 7 (5%) 0 35 (26%) 12 (9%) 1 (1%) 0
Metabolism and nutrition disorders
Anorexia 39 (29%) 3 (2%) 0 0 41 (30%) 3 (2%) 0 0
Dehydration ·· 2 (1%) 0 0 ·· 2 (1%) 0 0
Hyperglycaemia ·· 1 (1%) 0 0 ·· 1 (1%) 1 (1%) 0
(Table 3 continues on next page)
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Chemotherapy alone group Chemotherapy plus cetuximab group
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
(Continued from previous page)
Hypokalaemia ·· 1 (1%) 0 0 ·· 0 1 (1%) 0
Hypomagnesaemia ·· 0 0 0 21 (15%) 1 (1%) 0 0
Hyponatraemia ·· 0 0 0 ·· 2 (1%) 0 0
Musculoskeletal and connective tissue disorders
Pain 53 (40%) 5 (4%) 0 0 49 (36%) 4 (3%) 0 0
Nervous system disorders
Dizziness ·· 1 (1%) 0 0 ·· 0 0 0
Dysgeusia 20 (15%) 0 0 0 19 (14%) 0 0 0
Lethargy 99 (74%) 5 (4%) 0 0 110 (80%) 8 (6%) 0 0
Peripheral neuropathy 115 (86%) 7 (5%) 0 0 100 (73%) 1 (1%) 0 0
Stroke ·· 0 0 0 ·· 0 1 (1%) 0
Syncope ·· 0 0 0 ·· 1 (1%) 0 0
Psychiatric disorders
Agitation ·· 1 (1%) 0 0 ·· 0 0 0
Anxiety ·· 1 (1%) 0 0 ·· 0 0 0
Confusion ·· 0 0 0 ·· 1 (1%) 0 0
Renal and urinary disorders
Acute kidney injury ·· 0 1 (1%) 0 ·· 1 (1%) 0 0
Respiratory, thoracic, and mediastinal disorders
Hiccups ·· 0 0 0 ·· 1 (1%) 0 0
Laryngospasm ·· 0 0 0 ·· 1 (1%) 0 0
Skin and subcutaneous tissue disorders
Alopecia 31 (23%) 1 (1%) 0 0 31 (23%) 0 0 0
Nail changes ·· 0 0 0 24 (18%) 2 (1%) 1 (1%) 0
Palmar-plantar erythrodysesthesia syndrome 28 (21%) 1 (1%) 0 0 66 (48%) 4 (3%) 0 0
Pruritus ·· 0 0 0 ·· 1 (1%) 0 0
Skin rash 26 (19%) 1 (1%) 0 0 124 (91%) 18 (13%) 0 0
Vascular disorders
Peripheral ischaemia ·· 0 0 0 ·· 1 (1%) 0 0
Phlebitis ·· 1 (1%) 0 0 ·· 1 (1%) 2 (1%) 0
Thromboembolic event ·· 3 (2%) 5 (4%) 0 ·· 6 (4%) 2 (1%) 0
During postoperative chemotherapy period†
Blood and lymphatic system disorders
Anaemia 35 (30%) 0 1 (1%) 0 37 (32%) 0 0 0
Febrile neutropenia ·· 0 0 0 ·· 1 (1%) 0 0
Other (platelets) 35 (30%) 0 0 0 32 (28%) 0 0 0
Other (white cell count low) 18 (16%) 2 (2%) 0 0 23 (20%) 0 0 0
Ear and labyrinth disorders
Tinnitus ·· 1 (1%) 0 0 ·· 0 0 0
Gastrointestinal disorders
Abdominal pain ·· 1 (1%) 0 0 ·· 0 0 0
Constipation 18 (16%) 1 (1%) 0 0 28 (24%) 0 0 0
Diarrhoea 39 (34%) 2 (2%) 0 0 49 (43%) 2 (2%) 0 0
Mucositis oral 29 (25%) 0 0 0 49 (43%) 3 (3%) 0 0
Nausea 39 (34%) 1 (1%) 0 0 38 (33%) 1 (1%) 0 0
Vomiting ·· 3 (3%) 0 0 16 (14%) 2 (2%) 0 0
General disorders and administration-site conditions
Non-cardiac chest pain ·· 1 (1%) 0 0 ·· 0 0 0
Immune system disorders
Allergic reaction ·· 0 0 0 ·· 1 (1%) 1 (1%) 0
(Table 3 continues on next page)
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the appendix (pp 6–9, 12–15). The results from the 
interaction subgroup analysis of overall survival 
and progression-free survival are in figure 3 and the 
appendix (pp 10, 11).
Extended RAS/RAF testing was successfully completed 
on primary colorectal cancer samples from 140 patients 
in the trial previously classified as KRAS wild-type 
(codons 12, 13, and 61). 24 (17%) of these 140 patients had 
mutations identified, comprising 13 patients with KRAS 
mutations, four patients with NRAS mutations, and 
seven patients with BRAF mutations. These mutations 
were balanced between the groups of the study with 12 in 
the chemotherapy alone group (eight KRAS, one NRAS, 
three BRAF) and 12 in the chemotherapy plus cetuximab 
group (5 KRAS, 3 NRAS, 4 BRAF). All mutations were 
mutually exclusive. Restriction to an all RAS/RAF 
wild-type population revealed a HR for overall survival of 
1·64 (95% CI 0·92–2·93), with an observed median 
overall survival not reached (47·5–not reached) in the 
chemotherapy alone group and of 79·0 months (29·9–not 
reached) in the chemotherapy plus cetuximab group.
Treatment-related adverse events are in table 3. 
99 (77%) of 128 patients in the chemotherapy alone group 
and 103 (80%) of 129 patients in the chemotherapy plus 
cetuximab group completed 12 weeks of preoperative 
chemotherapy; 59 (52%) of 113 patients in the chemo-
therapy alone group and 62 (57%) of 108 patients in the 
chemotherapy plus cetuximab group completed 12 weeks 
of postoperative therapy. The proportion of patients 
requiring at least one dose modification was similar 
between the chemotherapy alone group (58 [45%] of 
128 in the preoperative period and 49 [43%] of 113 in 
the postoperative period) and the chemotherapy plus 
cetuximab group (60 [47%] of 129 in the preoperative 
Chemotherapy alone group Chemotherapy plus cetuximab group
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
(Continued from previous page)
Infections and infestations
Device-related infection ·· 2 (2%) 0 0 ·· 1 (1%) 0 0
Lung infection ·· 1 (1%) 0 0 ·· 1 (1%) 0 0
Sepsis ·· 0 0 0 ·· 1 (1%) 0 0
Investigations
Deranged liver function tests ·· 0 0 0 ·· 1 (1%) 0 0
Neutrophil count decreased 29 (25%) 6 (5%) 1 (1%) 0 26 (23%) 6 (5%) 3 (3%) 0
Metabolism and nutrition disorders
Anorexia 17 (15%) 1 (1%) 0 0 22 (19%) 0 0 0
Dehydration ·· 1 (1%) 0 0 ·· 1 (1%) 0 0
Hyperglycaemia ·· 1 (1%) 0 0 ·· 0 0 0
Hypokalaemia ·· 0 0 0 ·· 1 (1%) 1 (1%) 0
Musculoskeletal and connective tissue disorders
Back pain ·· 1 (1%) 0 0 ·· 0 0 0
Generalised muscle weakness ·· 0 0 0 ·· 1 (1%) 0 0
Pain 30 (26%) 2 (2%) 0 0 33 (29%) 2 (2%) 0 0
Nervous system disorders
Dysgeusia 17 (15%) 0 0 0 ·· 0 0 0
Lethargy 55 (47%) 5 (4%) 0 0 63 (55%) 2 (2%) 0 0
Peripheral neuropathy 58 (50%) 3 (3%) 0 0 61 (53%) 5 (4%) 0 0
Skin and subcutaneous tissue disorders
Nail changes 12 (10%) 0 0 0 20 (17%) 1 (1%) 0 0
Palmar-plantar erythrodysesthesia syndrome 16 (14%) 1 (1%) 0 0 40 (35%) 3 (3%) 0 0
Skin rash ·· 0 0 0 64 (56%) 6 (5%) 0 0
Vascular disorders
Phlebitis ·· 1 (1%) 0 0 ·· 0 0 0
Thromboembolic event ·· 3 (3%) 1 (1%) 0 ·· 1 (1%) 2 (2%) 1 (1%)
Data are n (%), where n is the number of patients who experienced that adverse event and grade combination. Grade 1–2 adverse events reported in 10% or more patients 
and all grade 3–5 events are shown. *The preoperative chemotherapy period includes all randomised patients: n=134 in the chemotherapy alone group, n=137 in the 
chemotherapy plus cetuximab group; the preoperative chemotherapy period lasted from the start of cycle 1 to the start of the last preoperative cycle plus 3 weeks for patients 
receiving chemotherapy regimen 1 or 3 or plus 4 weeks for patients receiving chemotherapy regimen 2. †Only patients who had surgery and postoperative chemotherapy are 
included in the postoperative chemotherapy period, n=116 in the chemotherapy alone group, n=115 in the chemotherapy plus cetuximab group; the postoperative 
chemotherapy period lasted from the start of the first postoperative chemotherapy cycle to the start of the last postoperative cycle plus 3 weeks for patients receiving 
chemotherapy regimen 1 or 3 or plus 4 weeks for patients receiving chemotherapy regimen 2.
Table 3: Adverse events during the preoperative and postoperative chemotherapy periods
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period and 48 [44%] of 108 in the postoperative period). 
The proportion of patients requiring at least one dose 
delay was also similar between the chemotherapy alone 
group (65 [51%] of 128 in the preoperative period and 
38 [34%] of 113 in the postoperative period) and the 
chemotherapy plus cetuximab group (63 [49%] of 129 in 
the preoperative period and 39 [36%] of 108 in the 
postoperative period). There were 14 premature with-
drawals from study treatment due to toxicity, six (4%) of 
134 in the chemo therapy alone group and eight (6%) of 
137 in the chemotherapy plus cetuximab group.
The proportion of patients having at least 
one preoperative grade 3 or worse toxicity and any post-
operative grade 3 or worse toxicity was similar between 
the chemotherapy alone group (63 [47%] of 134 in the 
preoperative period and 26 [22%] of 116 in the post-
operative period) and the chemotherapy plus cetuximab 
group (72 [53%] of 137 in the preoperative period and 
34 [30%] of 115 in the postoperative period; table 3).
The most common grade 3–4 adverse events reported 
were neutrophil count decreased (26 [19%] of 134 in 
the chemotherapy alone group vs 21 [15%] of 137 in 
the chemotherapy plus cetuximab group), diarrhoea 
(13 [10%] vs 14 [10%]), skin rash (one [1%] vs 22 [16%]), 
thromboembolic events (ten [7%] vs 11 [8%]), lethargy 
(ten [7%] vs nine [7%]), oral mucositis (three [2%] vs 
14 [10%]), vomiting (seven [5%] vs seven [5%]), peripheral 
neuro pathy (eight [6%] vs five [4%]), and pain (six [4%] vs 
six [4%]). The most common serious adverse events 
reported of any grade were diarrhoea (nine [7%] vs 
seven [5%]), thromboembolic events (nine [7%] vs 
seven [5%]), vomiting (seven [5%] vs five [4%]), fever 
(six [4%] vs three [2%]), sepsis (two [1%] vs five [4%]), and 
device-related infection (two [1%] vs five [4%]).
There were 26 drug-related serious adverse events in 
the chemotherapy alone group and 32 in the chemo-
therapy plus cetuximab group (appendix pp 30, 31) There 
were five deaths potentially related to treatment (appendix 
p 29). Three of these related to systemic treatment, 
one in the chemotherapy alone group (heart failure) 
and two in the chemotherapy plus cetuximab group 
(one pulmonary embolism and interstitial lung disease 
and one pulmonary embolism). One patient died of 
bronchopneumonia within 30 days of surgery in the 
chemotherapy plus cetuximab group. Another patient 
died of cardiac arrest within 90 days of surgery in the 
same treatment group and, although outside the protocol 
definition, this death might have been related to surgery. 
Surgical complications were reported in 28 (25%) of 
113 patients in the chemotherapy alone group and 
27 (25%) of 108 patients in the chemotherapy plus 
cetuximab group (table 2). Protocol violations are 
recorded in the appendix (pp 32, 33).
Discussion
The interim analysis of the primary endpoint of the 
New EPOC study showed a significantly shorter 
progression-free survival when cetuximab was added to 
perioperative chemotherapy, for patients with resectable 
colorectal liver metastasis.5 Although progression-free 
survival has accepted validity as a surrogate endpoint, in 
the context of such an unexpected finding, the overall 
survival assumes a greater importance, despite being a 
secondary endpoint. This mature analysis found that 
the detriment in progression-free survival is no longer 
significant, although median overall survival was 
26 months shorter for patients receiving cetuximab and 
chemotherapy than for those receiving chemotherapy 
alone. This finding suggests that the premature closure 
of the trial, its primary limitation but mandated by the 
trial steering committee, did not influence the outcome. 
If the study were to be repeated, translational endpoints 
would be prioritised. However, such a choice was neither 
standard nor technically feasible in 2005, when the 
study started.
The baseline characteristics of the chemotherapy plus 
cetuximab group are prognostically less favourable, with 
more patients having synchronous disease and a 
metastasis larger than 3 cm. However, these differences 
are small and not significant. Furthermore, review of the 
predefined subgroup analyses reveals the detriment with 
cetuximab in this present study occurred in patients with 
favourable characteristics (not poorly differentiated, not 
N2 disease, fewer than four metastases). The subset with 
unfavour able prognostic features (poorly differentiated 
histology, N2 disease, or four or more metastases) did 
not benefit from addition of cetuximab to chemotherapy, 
but were not disadvantaged. As such, there is no evidence 
to suggest that any difference in the baseline variables 
contributed to the poor outcome of the cetuximab group.
The quality of surgery following systemic therapy 
might have affected study outcome. At the time of the 
first publication it was not possible to present complete 
surgical data since not all patients had, at that time, 
undergone protocol-defined surgery. These data are now 
complete. More patients in the chemotherapy plus 
cetuximab group than in the chemotherapy alone group 
did not undergo an operation, in most cases because of 
progressive disease. Of the patients who underwent an 
operation, some were treated with ablation with or 
without surgery. This choice was not permitted in the 
protocol, but patient management was always at the 
discretion of the clinician. Additional protocol violations 
included the two patients in the chemotherapy alone 
group who were not operated on during the period 
allowed by the protocol, because of a complete 
radiological response, and the two patients in the 
chemotherapy plus cetuximab group who were operated 
on, but not resected, because of a complete response.
Although it is natural to focus on the unexpected 
outcome in the experimental group of the trial, the survival 
achieved in the chemotherapy alone group should not be 
overlooked. Indeed, the 5-year survival in this group is 
comparable to the best of any case series,1 despite the 
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inclusion of borderline resectable patients. Furthermore, 
there was only one 30-day mortality in the 221 patients that 
underwent surgery, attesting to the quality of care in 
high-volume liver surgery centres in the UK.
Post-hoc analyses of other trials in advanced colorectal 
cancer have shown inferior survival outcomes with the 
addition of anti-EGFR therapies to chemotherapy for 
KRAS-mutated and all RAS-mutated cancers,7,11–13 and all 
RAS wild-type testing before EGFR therapy is now 
mandatory. Now, patients with any RAS or BRAF 
mutation would not be given cetuximab.14 Accordingly, 
extended RAS/RAF testing was done on all available 
New EPOC samples. The HR point estimate for 
detriment with cetuximab in the all RAS/RAF wild-type 
population was almost identical to that in the whole trial 
population, although it was not significant. This finding 
was not observed in the patients who had additional 
RAS/RAF pathway mutations discovered in the primary 
cancer on further testing, but the numbers are 
insufficient to make any definite conclusion.
Data to support a biological explanation for this 
unexpected trial outcome are accumulating. High 
expression of the microRNA miR-31–3p in primary 
colorectal cancer of patients with metastatic disease 
treated with cetuximab or panitumumab has been shown 
to be associated with resistance to EGFR and disease 
progression.15 In the New EPOC cohort, it was not 
possible to identify a patient subgroup in which 
miR-31–3p expression levels were associated with an 
improvement in outcomes when cetuximab was added to 
chemotherapy.16 It is nevertheless interesting to observe 
that the poorer outcomes associated with the addition of 
cetuximab to chemotherapy were limited to patients with 
high miR-31–3p expression in the primary cancer. This 
detrimental effect was not observed in patients with low 
miR-31–3p expression levels.16
Previous studies have suggested a predictive role for 
the expression of the EGFR ligands amphiregulin 
(AREG) and epiregulin (EREG). In 2016, survival benefit 
from the use of panitumumab in advanced colorectal 
cancer was observed in patients with high AREG or 
EREG expression, or both, but not in those with low 
expression.17 By contrast, in New EPOC, high ligand 
expression was associated with a decreased progression-
free survival with the addition of cetuximab, whereas 
patients with low ligand expression had a similar 
progression-free survival irrespective of treatment 
allocation.18 Rationalising these results with those of 
other studies is challenging,17,19–21 but serves to highlight 
the importance of biology, and possibly of an intact 
EGFR signalling pathway, to the detriment in outcomes 
with the addition of cetuximab. Mismatch repair status 
was not routinely measured during the period of study 
recruitment and cannot be reliably reported. This will be 
assessed in the translational analysis.
Although studies of anti-EGFR therapies in advanced 
disease have mostly been positive, those in the adjuvant 
setting have not,22,23 with a trend towards detrimental 
outcomes in older patients.23 In the New EPOC study, 
most patients were upfront operable and, therefore, the 
predominant effect of systemic intervention was likely to 
be on micrometastatic disease; as such, these results are 
consistent with the adjuvant anti-EGFR therapy data. 
Furthermore, and as discussed above, the survival of 
patients with poorer prognostic features did not seem to 
be affected by the addition of cetuximab. This trial, 
therefore, does not preclude the possibility that there 
might be benefit from the addition of cetuximab in 
patients with more advanced and inoperable disease.6,7 
The translational studies currently underway will 
hopefully provide an understanding of this possibility, 
thereby further informing the appropriate selection of 
patients for anti-EGFR therapies.
In the advanced disease setting, right-sided metastatic 
colon cancer has been reported to be less responsive to 
EGFR inhibition,24 the biology of which is currently being 
interrogated. In the New EPOC trial, survival of patients 
with liver metastases from right-sided cancers was 
affected more than that of patients with left-sided cancers 
by the addition of cetuximab, although there were 
relatively few right-sided cancers and the difference was 
not significant. Therefore, the biology underlying the 
right versus left phenomenon seen in advanced disease 
with EGFR inhibition in the neoadjuvant setting should 
be investigated in future trials.
Further interrogation of the progression events in the 
New EPOC population has revealed some informative 
observations.25 First, additional data collected after the 
interim analysis showed that there were numerically 
more multisite progressions in the chemotherapy plus 
cetuximab group than in the chemotherapy alone group. 
Second, this updated analysis shows post-progression 
survival to be shorter for the chemotherapy plus 
cetuximab group. Therefore, the addition of cetuximab 
seems to have not only accelerated disease progression, 
but also might have led to the development of a more 
aggressive disease genotype and phenotype. Visual 
inspection of the survival curves suggests that 
progression was associated with early death in the 
chemo therapy plus cetuximab group, but not in the 
chemotherapy alone group. These early deaths were 
mainly attributable to disease pro gression. The trans-
lational studies that are underway will be crucial to 
explaining these complex observations.
Overall, we have shown that survival in patients with 
operable colorectal liver metastases is significantly worse 
with the use of cetuximab in combination with chemo-
therapy in the perioperative setting than with chemo-
therapy alone. This finding is robust, with no apparent 
confounding variables, and suggests that biological 
intervention in molecularly complex cancers might have 
unintended consequences. Cetuximab should not be 
used as neoadjuvant therapy in patients with operable 
colorectal liver metastases.
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